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health record based process to routinely assess and manage car-
diovascular disease (CVD) risk. METHODS: This project was
pilot tested in one Geisinger Clinic using EpiCare’s® EHR
system. Five computerized procedures were tested during routine
encounters to: 1) Deploy an automated protocol to identify
patients meeting criteria for CVD risk assessment; 2) determine
data elements missing to assess heart attack risk; 3) automati-
cally consent and order lab and patient self-reported risk ques-
tionnaires to assess risk; 4) activate a modiﬁed Framingham
CVD formula to calculate individual patient risk; and 5) engage
patients at moderate to high risk to review risk factors and deﬁne
goals. RESULTS: Over a 12-month period, 1610 patients were
eligible for screening, all of whom were missing data on one or
more CVD risk factors. Of these, orders for labs and question-
naire were placed for 27%; of these, 93% completed some or all
measures and 86% of those asked completed the online risk
assessment questionnaires. Using a modiﬁed Framingham risk-
scoring algorithm, 36% patients who were fully assessed, were
at moderate or high risk of a heart attack and were scheduled to
set goals to reduce their risk. Almost half of these patients com-
pleted their goal setting module. Goals were ﬁled back to the
EHR as a reference for monitoring patient progress. CONCLU-
SIONS: This preliminary test of a new model for CVD risk man-
agement suggests that automated protocols based on the EHR
can be used to routinely identify, assess and manage cardiovas-
cular disease risk. Primary care physicians can use EHR based
processes to improve patient management.
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OBJECTIVES: Non-achievement of combined optimal lipid
values (OLVs; LDL-C, HDL-C, and triglyceride [TG]) is associ-
ated with a 45% increase in cardiovascular events. Multiple lipid
abnormalities may require combination therapy, however sparse
data are available comparing marketed combination products
(extended release niacin/lovastatin [ERN/L] and simvastatin/eze-
timibe [S/E]). We modeled OLV attainment with ERN/L, S/E, and
components within a managed care (MCO) database.
METHODS: Patients were selected from a 2.1 million record
database based on: lipid panel between 1/1/00 and 12/31/01, no
concomitant lipid therapy, and continuous eligibility for 24
months. Initial lipid values and cardiovascular risk status (deter-
mined by ICD-9/CPT codes, prescription records) for each
patient was identiﬁed, and treatment effects were modeled using
product labeling at maximum doses. OLVs were based upon
NCEP ATP-III, AHA Women’s guidelines, or ADA guidelines.
RESULTS: We analyzed 44,351 patients; 50% male, age 65 + 13
years, and baseline lipids: LDL-C 131 + 35mg/dL, HDL-C 48 +
15mg/dL, TG 159 + 77mg/dL. At baseline, 10.1% achieved
OLVs which increased with ERN/L 56.1%, S/E 48.4%, ERN
36.4%, L 35.6%, S 42.3%, and E 18.4% (chi-square p < 0.05
all vs baseline; ERN/L vs S/E, ERN, and L; S/E vs S and E). In
2° prevention (N = 20,948), OLV increased from 8.2% to 51.1%
ERN/L, 50.4% S/E, 27.9% ERN, 31.8% L, 45.0% S, 17.7% E
(p < 0.05 for vs baseline; ERN/L vs ERN and L; S/E vs S and E).
In diabetes (N = 8,164), OLV increased from 7.4% to 50.5%
ERN/L, 46.0% S/E, 28.2% ERN, 30.2% L, 41.9% S, 16.4% E
(p < 0.05 all vs baseline; ERN/L vs S/E, ERN, and L; S/E vs E),
with similar results in 1° prevention (N = 23,403). CONCLU-
SIONS: In this MCO population, OLVs were best achieved with
ERN/L versus S/E. In a broad sprectrum of risk populations,
ERN/L achieved signiﬁcantly greater OLVs than each of it’s indi-
vidual components, in contrast to S/E.
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OBJECTIVE: This prospective, observational study evaluates the
medication utilization patterns and cost of treatment of patients
treated for myocardial infarction (MI) at a government institu-
tion in Kerala, India. METHODS: Patients with a diagnosis of
MI and received streptokinase (SK) therapy are enrolled into the
study. The following data is collected: demographics, clinical
outcomes, laboratory results, ECG resolution, drug utilization
parameters, and cost data from a patient perspective. The cost
of drug therapy for each patient is calculated utilizing the
Current Index of Medical Specialties 2004. Logistic regression
univariate analysis is conducted to determine the association
between outcome and treatment factors with p < 0.05.
RESULTS: One hundred ﬁfty patients are enrolled. The mean
age is 59.1 years and 77% of the patients are male. The average
pain to treatment period for SK therapy is 4.69 hours, while the
average door to treatment period is 79.9 minutes. A total of
34.7% of the patients experience a post SK ECG resolution
above 70% and in hospital mortality is 12.67%. Logistic regres-
sion results indicate that greater than 70% resolution on ECG
is associated with shorter treatment window period, non ante-
rior infarct, dyslipidemia, lower CPK-1 level, and lower rate of
mortality. Increased mortality is associated with heart block,
hypotension, low ECG resolution, arrhythmias, low ejection
fraction, CHF, and less use of beta blockers, nitrates, ace
inhibitors, and atorvastatin. The average cost of care to the
patient is Rs 5600.15 (SD Rs 13762.87). The average cost to the
hospital for free medicines is Rs 2629.06 (SD Rs 1515.22).
Patients who had at least 70% ECG resolution have an average
cost of Rs 4090.28, while patients who had less have an average
cost of Rs 5539.98. CONCLUSION: Management of myocar-
dial infarction utilizing SK appears to improve clinical outcomes
and be cost-effective in a government setting in Kerala, India.
PCV8
OUTCOMES OF CONGESTIVE HEART FAILURE INPATIENTS
TREATED WITH NESIRITIDE
Mahoney A, He J,Wang C, Grifﬁn B, Burleigh E
Solucient, Berkerley Heights, NJ, USA
OBJETIVES: Nesiritide is indicated for the intravenous treat-
ment of patients with acutely decompensated heart failure who
have dyspnea at rest or with minimal activity. In a recent study
it was recommended the drug be used only for inpatient settings.
We investigated effectiveness of Nesiritide in a group of Con-
gestive Heart Failure (CHF) inpatients using Solucient’s
ACTracker inpatient database. METHODS: A cohort of 28,332
Congestive Heart Failure patients discharged from 21 hospitals
from 4/2003 to 6/2005 was selected with 7,668 patients treated
with nesiritide as study group and a comparison group of 20,664
non Nesiritide treated patients. Chi-Square and t tests were used
to compare the two groups for mortality rate and hospital length
of stay (LOS) respectively. Conditional Logistic regression was
